What Is Survodutide and How Does It Work?

Survodutide, also designated BI 456906, is a once-weekly injectable peptide co-agonist that targets two receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. That dual mechanism separates it from single-target GLP-1 agents. GLP-1 receptor activation suppresses appetite and slows gastric emptying; glucagon receptor activation increases energy expenditure and promotes fat breakdown in the liver. The combination is the scientific rationale behind Boehringer Ingelheim's interest in MASH, a liver disease with limited approved treatment options.

Boehringer Ingelheim is developing survodutide in partnership with Zealand Pharma, which originally synthesized the molecule. Zealand licensed it to Boehringer Ingelheim in 2011 under a collaboration agreement. The compound is a synthetic peptide analog, not a small molecule, and it is administered subcutaneously. It has no approved pharmaceutical form under any brand name as of mid-2025.

Phase 2 Readouts: What the Numbers Showed

The most cited Phase 2 data for survodutide in obesity came from a randomized, placebo-controlled trial published in The Lancet Diabetes and Endocrinology in 2024. The trial enrolled 387 adults with overweight or obesity across multiple sites. Participants receiving the highest dose studied (4.8 mg weekly) achieved a mean body weight reduction of approximately 14.9 percent from baseline at 46 weeks, compared with roughly 2.8 percent in the placebo group. The trial was not powered for cardiovascular outcomes and did not include participants with type 2 diabetes as a primary population.

For MASH, Boehringer Ingelheim reported Phase 2 results from a separate study in 2024. That trial evaluated survodutide in adults with biopsy-confirmed MASH and liver fibrosis at stages F1 through F3. At 48 weeks, 47 percent of participants in the pooled survodutide arms achieved MASH resolution without worsening of fibrosis, compared with 14 percent on placebo. Fibrosis improvement of at least one stage without worsening of MASH occurred in 34 percent of survodutide-treated participants versus 22 percent on placebo. These are Phase 2 figures from a relatively small sample and are not confirmatory evidence of efficacy.

Both Phase 2 programs reported gastrointestinal adverse events, primarily nausea, vomiting, and diarrhea, as the most common side effects. These are consistent with the GLP-1 class broadly. Discontinuation rates due to adverse events were higher in the survodutide arms than in placebo arms, a pattern the Phase 3 programs will need to characterize more precisely.

Current Phase 3 Status

Boehringer Ingelheim announced the start of Phase 3 development for survodutide in both obesity and MASH in 2024. The MASH Phase 3 program, named THUNDER, was initiated and registered on ClinicalTrials.gov. The obesity Phase 3 program is also underway. These trials are designed as the pivotal studies that would support a future regulatory submission, but enrollment and completion timelines extend well into the late 2020s based on standard Phase 3 durations for metabolic disease.

Phase 3 trials for MASH typically require histological endpoints confirmed by liver biopsy at 48 to 72 weeks, followed by longer-term follow-up for outcomes such as cirrhosis prevention. The FDA has issued draft guidance on MASH endpoints, and Boehringer Ingelheim has indicated alignment with those frameworks. No interim readout from the Phase 3 MASH program has been publicly reported as of mid-2025.

The obesity Phase 3 program will need to demonstrate superiority over placebo on body weight reduction and, depending on the label sought, may require cardiovascular outcome data. No cardiovascular outcomes trial for survodutide has been announced publicly as a standalone study, though the Phase 3 obesity trials may collect relevant safety data.

Regulatory Standing: No Approval Exists

Survodutide has not been approved by the FDA, the European Medicines Agency, or any other major regulatory body as of mid-2025. There is no branded prescription product. It is an investigational compound, meaning it can only be administered legally in the context of a registered clinical trial. Readers should not confuse survodutide with approved GLP-1 class drugs such as semaglutide (approved as Ozempic and Wegovy by the FDA) or tirzepatide (approved as Mounjaro and Zepbound by the FDA). Those are distinct molecules with distinct regulatory histories.

Research-chemical versions of survodutide sold online are not FDA-approved, not manufactured under pharmaceutical-grade quality controls, and have no verified safety or efficacy data outside of clinical trial settings. The compound's Phase 3 trials are ongoing, and regulatory submission would follow completion and analysis of those trials, a process that typically takes several additional years.

Boehringer Ingelheim has not filed a New Drug Application or Biologics License Application for survodutide with the FDA as of mid-2025. No Breakthrough Therapy designation or Fast Track designation for survodutide has been publicly confirmed by the FDA, though the agency does not always publicize such designations at the time of granting.

What Changed in 2024 and Early 2025

The most significant development in the survodutide timeline was the publication of Phase 2 MASH data in a peer-reviewed journal in 2024 and the simultaneous announcement of Phase 3 initiation. Prior to 2024, survodutide was primarily tracked as an obesity candidate; the MASH data elevated its profile considerably because MASH has fewer approved therapies than obesity does. Resmetirom (Rezdiffra) received FDA approval for MASH in March 2024, creating a reference point for what Phase 3 MASH trials need to demonstrate.

Zealand Pharma, as the originating partner, has continued to receive milestone payments tied to survodutide's development progress. Zealand's public financial disclosures have referenced survodutide milestones in 2024, which confirms the program remains active and on track per the partnership agreement. Zealand does not control the regulatory strategy; Boehringer Ingelheim leads development.

No Phase 3 efficacy readout is expected before 2026 at the earliest based on trial registration timelines and standard enrollment periods for MASH studies. The obesity Phase 3 timeline may differ. Readers tracking this compound should monitor ClinicalTrials.gov entries and Boehringer Ingelheim's pipeline disclosures for updates, as interim analyses or protocol amendments can shift timelines.

How Does Survodutide Compare to Other GLP-Class Compounds in Development?

Survodutide sits in a crowded field of GLP-1-based compounds at various stages of development. Retatrutide (LY3437943), Eli Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors, is also in Phase 3 for obesity. Cagrilintide, an amylin analog being developed in combination with semaglutide as CagriSema by Novo Nordisk, is in Phase 3 as well. Each compound has a different receptor profile, different Phase 2 weight-loss numbers, and different timelines.

Survodutide's dual GLP-1 and glucagon mechanism is most directly comparable to retatrutide's glucagon component, though retatrutide adds GIP receptor activity. In head-to-head terms, no randomized trial has compared survodutide directly to any other GLP-class compound. Comparisons across separate trials are limited by differences in patient populations, doses studied, and trial durations. The Phase 2 obesity weight-loss figure of approximately 14.9 percent at 46 weeks is lower than some Phase 2 figures reported for retatrutide and tirzepatide, though cross-trial comparisons are not reliable evidence of relative efficacy.

Survodutide's strongest differentiation argument, at this stage, rests on the MASH data. MASH is a condition where GLP-1 agents have shown activity but where the glucagon receptor component may add hepatic benefit through increased fat oxidation in liver cells. That hypothesis is supported by preclinical data and the Phase 2 biopsy results, but it requires Phase 3 confirmation.